Compare Ford Motor Company (F) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs Recursion Pharmaceuticals Inc — how do they compare? Ford Motor Company trades at $14.14 (market cap $56.50B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.75B). The key difference: Ford Motor Company is far larger — about 32.3× Recursion Pharmaceuticals Inc's market cap, and Ford Motor Company pays a 4.23% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| F | RXRX | |
|---|---|---|
Market Cap | $56.50B | $1.75B |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $6.79 |
52-Week Low | $10.82 | $2.84 |
Enterprise Value | $185.53B | $1.17B |
Dividend Yield | 4.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford (F) trades at $14.09, up 1.15% today, with a bullish technical signal from moving averages and a consensus analyst price target of $15.00. Recent earnings show volatility with Q1 2026 beating expectations but Q4 2025 missing, while revenue grew to $187.27 billion in 2025. The company maintains strong cash flow from operations at $21.28 billion and announced a $0.15 dividend for H1 2026, though net income was negative at -$8.18 billion due to high costs.
Ford's outlook is mixed, with opportunities from EV expansion and labor stability, but risks include profit margin pressure and rising debt. Analysts are cautiously optimistic with 34% buy ratings, yet investors should weigh competitive threats and macroeconomic headwinds against the stock's low P/E of 11.84 and dividend yield.
Recursion Pharmaceuticals (RXRX) trades at $3.07, down 8.08% in the last session, reflecting ongoing investor concerns about its financial performance. The stock shows a bearish technical signal with moving averages indicating selling pressure, while the company continues to report significant losses with a net income margin of -851.51% for 2025. Recent earnings have consistently beaten expectations, and analyst sentiment remains mixed with a consensus price target of $7.83 representing substantial upside potential from current levels.
The outlook for RXRX hinges on its ability to translate its AI-driven drug discovery platform into sustainable revenue growth and eventual profitability. While the company maintains analyst support and strong institutional backing, significant execution risks remain given its substantial cash burn and negative profitability metrics. The stock presents a high-risk, high-reward opportunity for investors willing to bet on the company's long-term technology potential despite current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
